Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis - Report - MDSpire
Advertisement
Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis
Clinical Report: Tirofiban's Effectiveness in Acute Ischemic Stroke Without LVO
Overview
This systematic review and meta-analysis demonstrate that tirofiban significantly improves 90-day functional outcomes in patients with acute ischemic stroke without large or medium vessel occlusion. While not associated with increased risk of severe bleeding or mortality, tirofiban does carry a higher risk of peripheral bleeding, which should be monitored closely.
Background
Acute ischemic stroke (AIS) without large- or medium-vessel occlusion (non-LVO/MVO) constitutes a significant portion of AIS cases, yet treatment options remain limited. Tirofiban, a glycoprotein IIb/IIIa receptor antagonist, has been explored as a potential therapeutic option, but evidence regarding its efficacy and safety has been inconsistent. Understanding the role of tirofiban in this patient population is crucial for improving clinical outcomes.
Data Highlights
Outcome
Odds Ratio (OR)
95% Confidence Interval (CI)
p-value
Excellent functional outcome (mRS 0–1)
1.66
1.34–2.06
< 0.001
Favorable functional outcome (mRS 0–2)
1.79
1.30–2.47
< 0.001
Symptomatic intracerebral hemorrhage (sICH)
4.02
0.91–17.70
0.07
90-day mortality
1.06
0.53–2.12
0.87
Peripheral bleeding
1.87
1.32–2.66
< 0.001
Key Findings
Tirofiban significantly increases the likelihood of achieving excellent functional outcomes at 90 days (OR 1.66).
It also improves the chances of favorable functional outcomes (OR 1.79).
No significant increase in the risk of symptomatic intracerebral hemorrhage (sICH) was observed (OR 4.02, p=0.07).
There was no significant difference in 90-day mortality (OR 1.06).
Tirofiban was associated with a higher risk of peripheral bleeding (OR 1.87).
Functional benefits were primarily noted in patients without prior intravenous thrombolysis (IVT).
Clinical Implications
Clinicians should consider tirofiban as a potential treatment option for patients with non-LVO/MVO acute ischemic stroke, particularly in those not previously treated with IVT. However, the increased risk of peripheral bleeding necessitates careful monitoring during treatment.
Conclusion
Tirofiban shows promise in enhancing functional recovery in non-LVO/MVO acute ischemic stroke patients, though its clinical application, especially post-IVT, requires further investigation. Ongoing monitoring for peripheral bleeding is essential.
